Sanofi, Japanese firm team up for monoclonal antibody

05/14/2009 | Reuters

Sanofi-Aventis agreed to co-develop Kyowa Hakko Kirin's anti-LIGHT fully human monoclonal antibody as a treatment for inflammation. The licensing deal, worth as much as $315 million, grants Sanofi worldwide rights to the drug, although the companies will jointly work on the product in Japan and Asia.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN